Cytoplasmic modulators of integrin binding/signalling

Abstract

The present invention relates to methods to identify modulators of integrin binding and/or signalling activity. Specifically the invention relates to a method to identify compounds which can alter the interaction between the cytoplasmic domain of a .beta..sub.1 integrin and a proteasome subunit protein.

Description

BACKGROUND

A significant characteristic of the immune and inflammatory responses is the movement of leukocytes from the bloodstream into specific tissues in response to various physiological signals. For example, certain subsets of lymphocytes "home" to various secondary lymphoid tissues such as lymph nodes or Peyer's patches, and eventually return to circulation. Other leukocytes such as granulocytes and monocytes, however, do not return to circulation after transmigration from the bloodstream. Movement of leukocytes from circulation is effected by a series of receptor/counter-receptor interactions which are coordinated by various specific membrane adhesion molecules.

Extravasation of leukocytes from the bloodstream �for review, see McEver, Curr. Opin. Cell Biol. 4:840-849 (1992)! is initially effected by a family of membrane glycoproteins termed selections which are either expressed constitutively or induced in response to specific cytokines. Binding of selections to their counterpart ligand brings leukocytes into close, but not static, contact with vascular endothelial cells. The "tethered" leukocyte then begins a "rolling" process along the endothelium which continues until additional molecular interactions firmly stabilize a specific cell/cell interaction. One of the molecular binding activities which results in the stable interaction is effected by a second family of surface glycoproteins called integrins which possess a higher binding affinity for their respective ligands than selections.

The integrins are heterodimeric surface molecules comprised of an .alpha. and a .beta. subunit in non-covalent association. All integrins are transmembrane proteins with counter-receptor binding activity localized in the extracellular domain. Integrins also possess relatively short cytoplasmic regions which participate in transmembrane signaling events. Integrins are capable of interacting with other cell-bound counter-receptors and components of the extracellular matrix, as well as soluble factors. Binding of extracellular ligands leads to crosslinking and localized clustering of integrins �Miyamoto, et al., Science 267:833, 1995! and formation of focal adhesions wherein the clustered integrin cytoplasmic domains associate with cytoskeletal components including, for example, actin filaments �Pavalko and Otey, Proc. Soc. Exp. Biol. Med. 205:32767, 1994, and Gumbiner, Neuron 11:551, 1993!. While most investigations into integrin physiological activity have focused on identifying specific counter-receptors using immunological methodologies as discussed infra, less is known about the specific interactions of integrins with cytoplasmic components. Mutation studies, however, have indicated that the cytoplasmic sequences are required for integrin association with focal contacts �LaFlamme, et al., J. Cell. Biol. 117:437 (1992)!. Other data discussed infra support this observation.

While numerous integrins have been identified, certain subsets are unique to leukocytes, with each member of the subset having characteristic cell-specific expression and counter-receptor binding properties. Of leukocyte-specific integrins, at least three .beta..sub.2 integrins are known, each comprised of a unique .alpha. subunit in association with a .beta..sub.2 subunit (designated CD18) �Kishimoto, et al., Cell 48:681-690 (1987)!. For a recent review of the state of the art with regard to .beta..sub.2 integrins, see Springer, Cell 76:301-314 (1994). CD11a/CD18, also known as .alpha..sub.L .beta..sub.2 or LFA-1, is expressed on all leukocytes and has been shown to bind to ICAM-1, ICAM-2, and ICAM-3. CD11b/CD18, also know as .alpha..sub.M .beta..sub.2 or Mac-1, is expressed on polymorphonuclear neutrophils, monocytes and eosinophils and has been shown to bind to ICAM-1, complement factor iC3b, factor X, and fibrinogen. CD11c/CD18, also known as .alpha..sub.X .beta..sub.2 or p150,95, is expressed on monocytes, polymorphonuclear neutrophils and eosinophils and has been shown to bind to complement factor iC3b and fibrinogen. In addition, a fourth human .beta..sub.2 integrin, designated .alpha..sub.d .beta..sub.2, has recently been identified �Van der Vieren, et al., Immunity 3:683-690 (1995)!. Recently, it has been demonstrated that the actin-binding protein, filamin, directly binds to a cytoplasmic portion of .beta..sub.2 subunits �Sharma, et al., J. Immunol. 154:3461-3470 (1995)! which suggests a role one or more of for the .beta..sub.2 integrins in formation of focal contacts and cell motility in general �see review in Arnaout, Blood 75:1037 (1990)!.

A second subset of leukocyte specific integrins may be referred to as the .alpha..sub.4 integrins in view of the fact that both members of the family are comprised of a common .alpha..sub.4 subunit in association with either a .beta..sub.1 or .beta..sub.7 subunit. For a recent review, see Springer, supra. VLA-4, also referred to as .alpha..sub.4 .beta..sub.1 or CD49d/CD29, is expressed on most peripheral blood leukocytes except neutrophils and specifically binds VCAM-1 and fibronectin. LPAM-1, also known as .alpha..sub.4 .beta..sub.7, is expressed on all peripheral blood leukocytes and has been shown to bind MadCAM-1, fibronectin and VCAM-1. Expression of either of the .alpha..sub.4 integrins has also been demonstrated in a wide range of leukocyte cell types in lymphoid organs and in various tissues (Hemler et al., Immunol. Rev. 114:45-60, 1990; Kilshaw et al., Eur. J. Immunol. 20:2201-2207, 1990; Schweighoffer et al., J. Immunol. 151:717-729, 1993; and Lazarovits and Karsh, J. Immunol. 151:6482-6489, 1993). Consistent with the observed participation of .beta..sub.2 integrins in formation of focal contacts, presumably through filamin binding, it has previously been shown that cytoplasmic portions of .beta..sub.1 integrins directly bind .alpha.-actinin in vitro. While this interaction has not been demonstrated in vivo, it suggests physiological involvement of .beta..sub.1 integrins in cell mobility and/or maintenance of cell morphology �see review in Clark and Brugge, Science 268:233-238 (1995)!.

A number of in vitro and in vivo studies utilizing anti-.alpha..sub.4 monoclonal antibodies have indicated a role for the .alpha..sub.4 integrin pathophysiological conditions �see review, Lobb and Hemler, J. Clin. Invest. 94:1722-1728 (1994)!. For example, several investigations have provided evidence that .alpha..sub.4 integrins are involved in leukocyte emigration from peripheral blood into regions of inflammation (Weg, et al., J. Exp. Med. 177:561-566, 1992; Winn and Harlan, J. Clin. Invest. 92:1168-1173, 1993). These observations suggest that anti-.alpha..sub.4 antibodies may be capable of ameliorating integrin-associated disease states, and this therapeutic potential has been demonstrated in several animal disease state models. For example, bolus injection of antibodies to .alpha..sub.4 integrins delayed the onset of paralysis in rat and murine experimental allergic encephalomyelitis (Yednock, et al., Nature 356:63-66, 1992; Baron, et al., J. Exp. Med. 177:57-68, 1993). Prophylactic administration of anti-.alpha..sub.4 antibodies reduced ear swelling in murine contact hypersensitivity models (Ferguson, et al., J. Immunol. 150:1172-1182, 1993; Nakajima, et al., J. Exp. Med. 179:1145-1154, 1994). Further, anti-.alpha..sub.4 antibodies were shown to reduce infiltration of pancreatic islets and delay the onset of diabetes in non-obese diabetic mice which are prone to spontaneous development of type I diabetes (Yang, et al., Proc. Natl. Acad. Sci. (USA) 90:10494-10498. 1993; Burkly, et al., Diabetes 43:529-534, 1994; Baron, et al., J. Clin. Invest. 93:1700-1708, 1994). Still other in vivo studies using anti-.alpha..sub.4 antibodies suggest a role for .alpha..sub.4 integrins in allergic lung inflammation (Pretolani, et al., J. Exp. Med. 180:795-805 (1994); Milne and Piper, Br. J. Pharmacol. 112:82Pa(Abstr), 1994); inflammatory bowel disease (Podolsky, et al., J. Clin. Invest. 92:372-380, 1993); cardiac allograft rejection (Paul, et al., Transplantation 55:1196-1199, 1993); acute nephrotoxic nephritis (Mulligan, et al., J. Clin. Invest. 91:577-587, 1993); and immune complex mediated lung injury (Mulligan, et al., J. Immunol. 159:2407-2417, 1993).

Thus there exists a need in the art to identify molecules which bind to and/or modulate the binding and/or signalling activity of the integrins and to develop methods by which these molecules can be identified. The methods, and the molecules thereby identified, will provide practical means for therapeutic intervention in .alpha..sub.4 integrin-mediated immune and inflammatory responses.

BRIEF DESCRIPTION OF THE INVENTION

The present invention provides methods wherein modulators (i.e., activators or inhibitors) of integrin-proteasome subunit interaction can be identified. A general method involves: i) contacting an integrin or fragment thereof with a proteasome subunit or fragment thereof; ii) measuring binding between the integrin or fragment thereof and the proteasome subunit or fragment thereof; iii) measuring binding between the integrin or fragment thereof and the proteasome subunit or fragment thereof in the presence of a test compound; and iv) comparing the measurement in step (ii) and the measurement in step (iii). A change in degree of interaction, either enhancement (indicating the compound is an activator) or abatement (indicating that the compound is an inhibitor), is indicative of the potential use of the modulator in an in vivo system to effect the same change.

Numerous variations on the general method are contemplated by the invention. For example, a two hybrid system may be utilized to identify genes encoding potential modulators. In this system, an integrin is expressed in a host cell as a fusion protein with either a DNA binding domain or transactivation domain of a modular transcription factor. A proteasome subunit protein is also expressed as a fusion protein with which ever transcription factor domain is not utilized with expression of the integrin fusion protein. Interaction of the two fusion proteins results in reconstitution of the holo-transcription factor and permits expression of a reporter gene with a promoter specific for the transcription factor. Use of this system in the presence or absence of library cDNA can permit identification of genes that encode proteins which modulate the degree of reporter gene expression.

As another example, either the integrin or the proteasome subunit can be immobilized on a solid support. The binding partner not immobilized can then be labeled in such a manner to permit detection of its binding to the immobilized binding partner. Contacting the binding partners in the presence and absence of a putative modulator and measuring change in binding will permit identification of potential in vivo binding modulators. The non-immobilized binding partner may be labeled with a radioisotope, a fluorescent marker, or the like. Alternatively, the immobilized binding partner may be bound to a support which includes a compound that can be excited to emit light when in proximity to the binding partner. Association of the binding partner can thereby be quantitated by the degree of light emitted, and modulators identified by the degree to which the level of emitted light is changed.

Additional methods comprehended by the invention include immunological assays including radio-immuno assays, enzyme linked immunosorbent assays, sandwich assays and the like. Co-precipitation methods are also comprehended wherein an antibody immunospecific for one binding partner is utilized in a method in which the other binding partner is detectably labeled. Immunological assays may also include use of labeled antibodies specifically immunoreactive with a complex between the desired binding partners.

Numerous compounds are contemplated as being candidates for testing in methods of the invention. For example, antibody products which are immunoreactive with one binding partner and which modulate binding between the two molecules can be identified by the claimed method. Antibody products contemplated are monoclonal antibodies and fragments thereof, humanized antibodies and/or single chain antibodies. Other molecules which can be screened in the claimed method include peptides, small molecules and libraries composed of either of the same.

Modulators of .beta..sub.1 integrin/TRAP2 interaction identified by the methods of the invention are utilized in in vivo or in vitro to affect inflammatory processes involving lymphocytes. In addition, modulating compounds which bind to either the .beta..sub.1 integrin or TRAP2 are useful to monitor the level of its binding partner, either in a body fluid or biopsied tissue.

Those of ordinary skill in the art will readily appreciate that numerous variations of the claimed method are encompassed by the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is illustrated by the following examples relating to the isolation of a cDNA clone encoding a protein that interacts with a .beta..sub.1 integrin and methods to identify modulators of the interaction. Example 1 describes identification of genes from a B cell library which encode proteins that interact with .beta..sub.1 integrins. Example 2 addresses specificity of interaction of the identified protein with .beta..sub.1 integrin. Example 3 relates to mapping of sequences required for interaction between B171 and .beta..sub.1 integrin. Example 4 addresses applications for modulators identified by the method.

Example 1

Identification of Genes in a B Cell Library Encoding .beta..sub.1 Interacting Proteins

The two-hybrid system developed in yeast �Durfee, et al., Genes and Development 7:555-567 (1993)! was used to screen for products of a human B cell cDNA library which interact with the carboxy-terminus of the cytoplasmic tail of the .beta..sub.1 integrin subunit. The yeast two-hybrid screen is based on in vivo reconstitution of the GAL4 transcription factor and subsequent expression of a reporter gene driven by a GAL4 promoter. Briefly, GAL4 DNA-binding and transcription-activating domains are encoded on separate plasmids as portions of fusion proteins. Expression of the fusion proteins and interaction of the expression products results in association of the two GAL4 domains and ultimate expression of the .beta.-galactosidase reporter gene under transcriptional control of the GAL4 promoter.

In the present investigation, a "bait" plasmid (pAS1) was constructed that contained sequences encoding the GAL4-binding domain, a trp.sup.- selection requirement, a hemagglutinin (HA) epitope tag and cytoplasmic amino acid sequences of .beta..sub.1 integrin. The cytoplasmic domain for .beta..sub.1 was initially isolated from a HeLa cDNA library by standard hybridization techniques using an anti-sense probe beta1.d2 as set out in SEQ ID NO: 1.

AGAAGTAGGTATTCCTTCCTG (SEQ ID NO: 1)

Hybridization was carried out using 22 .mu.l Rapid Hyb solution (Amersham, Arlington Heights, Ill.), 100 .mu.l of 50 .mu.g/ml heparin, and the beta1.d2 probe previously labeled using a Random Primer Labelling kit (Boehringer Mannheim, Indianapolis, Ind.) according to manufacturer's suggested protocol. Hybridization was carried out at 42.degree. C. overnight and a final filter wash was performed in 1X SSC/0.1% SDS at 42.degree. C. The library sequence from a positive clone was subcloned into vector pCDNA1amp, after which the integrin cytoplasmic sequences were amplified by PCR for subsequent subcloning. The .beta..sub.1 integrin cytoplasmic domain was amplified by PCR using the primers set out in SEQ ID NOs: 2 and 3. ##STR1##

Amplification conditions included an initial incubation at 94.degree. C. for four minutes, followed by thirty cycles of: 94.degree. C. for one minutes, 50.degree. C. for two minutes, and 72.degree. C. for four minutes. The resulting product was sequenced to rule out PCR-derived errors and subcloned into plasmid pAS1. A yeast strain, Y190, was transformed with .beta..sub.1 /pAS1 by standard methods and grown in selective media (trp.sup.-) to mid-log phase. Cells were lysed in lysis buffer (containing 100 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 5% BME and 0.1% bromo phenol blue) and the equivalent of 5-6.times.10.sup.6 cells of protein was separated on a 12% polyacrylamide gel. Proteins in the gel were then transferred to a PVDF (Millipore) membrane by standard methods. Control lanes on the gel contained lysate from Y190 transformed with pAS1 vector alone (containing no .beta..sub.1 integrin-encoding sequences). Western blotting was performed using antibody 12CA5 immunospecific for the HA epitope tag (Boehringer Mannheim, Indianapolis, Ind.), and a goat anti-mouse IgG horse radish peroxidase (HRP) secondary antibody. Results indicated that the fusion protein .beta..sub.1 integrin cytoplasmic tail/HA/GAL4 DNA-binding domain was expressed at readily detectable levels.

A "target" vector was constructed with plasmid pACT modified to contain sequences encoding the GAL4 activation domain II fused to a human lymphocyte cDNA library inserted at the XhoI site and a leu.sup.- selection requirement. The .beta..sub.1 /pAS1-transformed Y190 cells were transformed by standard methods with the pACT-lymphocyte library DNA and cells grown under selective conditions (leu.sup.- /trp.sup.- /his.sup.- /13-aminothiazole). Only cells in which the GAL4 transcription factor reconstituted as a result of interaction occurred between .beta..sub.1 integrin cytoplasmic tail of the "bait" fusion protein and an unknown "target" (B cell library-derived) fusion protein survive. Resulting colonies were tested for .beta.-galactosidase (.beta.-gal) activity and two .beta.-gal positive clones were obtained.

Sequence analysis of the B cell cDNA-derived, pACT inserts identified revealed one sequence which encoded a portion of a known protein. The nucleotide and amino acid sequences for this clone, designated B171, are set out in SEQ ID NOs: 4 and 5, respectively. Comparison of the sequence of clone B171 with DNA and protein databases, via NCBI Blastn and Blastp, on or around Jul. 13, 1995 and again around Nov. 24, 1995, revealed that B171 has high sequence identity to three proteins: TRAP2 (gp or gb/U12596), 26S proteasome subunit p97 (GP or DBJ/D78151), 55.11 binding protein (gp or emb/X86446) which is related to the 26S proteasome subunit p97. B171 is also homologous to a lesser extent to a related protein p67 (gp or gb/U18247). An alignment of the four proteins with each other and with B171 suggests that the four proteins may be the same protein with sequencing errors or artifacts generated during cDNA synthesis explaining the discrepancies between them.

Example 2

Specificity of B171 Interaction With .beta..sub.1

The specificity of the interaction between B171 and .beta..sub.1 -integrin cytoplasmic tail was addressed by transforming B171 into Y190 strains previously transformed with variety of "baits" vectors (encoding any one of .beta..sub.1, .beta..sub.2, .beta..sub.7, .alpha..sub.L, and .alpha..sub.4 -integrin cytoplasmic tails) using standard methods of transformation and selection described above.

Results shown in Table 1 indicate that B171 specifically binds to .beta..sub.1 integrins and not to other integrins.

TABLE 1______________________________________.beta..sub.1 /Integrin Binding SpecificityBait Integrin .beta.-Galactosidase Activity______________________________________.beta..sub.1 +.beta..sub.2 -.beta..sub.7 -.alpha..sub.L -.alpha..sub.4 -______________________________________

Example 3

Localization of B171/.beta..sub.1 Binding Sites

In order to determine .beta..sub.1 sequences necessary for B171 binding, the cytoplasmic domain sequences of the .beta..sub.1 subunit, and various truncation mutants thereof, were cloned and utilized in the two hybrid screen. In this method, only cytoplasmic regions of the integrin subunit were cloned into the bait plasmid. The deletions in the .beta..sub.1 -integrin cytoplasmic tail were created using standard in vitro mutagenesis schemes using PCR with the primers used to generate each deletion as set out in SEQ ID NO: 6 to 9. Each of the primers used to amplify a deletion mutant was paired with the 5' primer set out in SEQ ID NO: 2. ##STR2##

The resultant truncation mutants are set out in SEQ ID NOs: 11 to 14, with the wild type sequence of .beta..sub.1 shown in SEQ ID NO: 10. ##STR3##

As shown in Table 2, the only .beta..sub.1 integrin mutant to still interact with B171 was B1D3. All the other deletions in the integrin cytoplasmic sequence abolish the interaction.

TABLE 2______________________________________TRAP2 Interaction with .beta..sub.1 Deletions______________________________________ B1 + B1D1 - B1D2 - B1D3 + B1D4 -______________________________________

Example 4

Applications for Modulating Compounds

Engagement of .alpha..sub.4 .beta..sub.1 has been shown to induce cytokine gene expression in eosinophils and macrophages �Yurochko, et al., Proc. Natl. Acad. Sci. (USA) 89:9034-9038 (1992) and Anwar, et al., J. Exp. Med. 177:839-843 (1993)!. Engagement with VCAM-1, matrix proteins, or monoclonal antibodies to .beta..sub.1, induces activation of NF.sub.k B �Lofquist, et al., Mol. Cell. Biol. 15:1737-1746 (1995)!. NF.sub.k B is associated with rapid production of inflammatory cytokines, chemokines and cell adhesion molecules in many different cell types including macrophages and endothelial cells �see reviews in Siebenlist, Ann. Rev. Cell Biol. 10:405-455 (1994) and Baeuerle, Ann. Rev. Immunol. 12:141-179 (1994)!.

It has also been demonstrated that proteasomes are involved in activation of NF.sub.k B, and the invention contemplates that TRAP2 association with the .beta..sub.1 integrin subunit also results in NF.sub.k B activation. Inhibitors of this interaction are therefore contemplated to function in vivo as potent anti-inflammatory agents. Development of a high throughput screening (HTS) method which permits rapid analysis of small molecule libraries, peptide libraries and antibodies will provide candidate anti-inflammatory agents for further in vivo analysis. A number of assays disclosed herein, e.g., two hybrid screening, scintillation proximity assay (SPA), various immuno-assays, including enzyme-linked immunosorbent assays (ELISA), etc., while not HST screening methodologies, per se, are amenable to identify binding modulators. SPA and ELISA, in particular, are useful in this respect and can be modified to permit high throughput screening.

Numerous modifications and variations as set forth in the above illustrative examples are expected to occur to those of ordinary skill in the art. Consequently, only such limitations as appear in the appended claim should be placed on the invention.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 14(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:AGAAGTAGGTATTCCTTCCTG21(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:GGAAGATCTTGAAGCTTTTAATGATAATTC30(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:GGAAGATCTTCATTTTTCCTCATACTTCGG30(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1631 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA(ix) FEATURE:(A) NAME/KEY: CDS(B) LOCATION: 1..1437(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:GACAAGTACCTGTACTCCTCTGAGGACTACATTAAGTCAGGAGCTCTT48AspLysTyrLeuTyrSerSerGluAspTyrIleLysSerGlyAlaLeu151015CTTGCCTGTGGCATAGTGAACTCTGGGGTCCGGAATGAGTGTGACCCT96LeuAlaCysGlyIleValAsnSerGlyValArgAsnGluCysAspPro202530GCTCTGGCACTGCTCTCAGACTATGTTCTCCACAACAGCAACACCATG144AlaLeuAlaLeuLeuSerAspTyrValLeuHisAsnSerAsnThrMet354045AGACTTGGTTCCATCTTTGGGCTAGGCTTGGCTTATGCTGGCTCAAAT192ArgLeuGlySerIlePheGlyLeuGlyLeuAlaTyrAlaGlySerAsn505560CGTGAAGATGTCCTAACACTGCTGCTGCCTGTGATGGGAGATTCAAAG240ArgGluAspValLeuThrLeuLeuLeuProValMetGlyAspSerLys65707580TCCAGCATGGAGGTGGCAGGTGTCACAGCTTTAGCCTGTGGAATGATA288SerSerMetGluValAlaGlyValThrAlaLeuAlaCysGlyMetIle859095GCAGTAGGGTCCTGCAATGGAGATGTAACTTCCACTATCCTTCAGACC336AlaValGlySerCysAsnGlyAspValThrSerThrIleLeuGlnThr100105110ATCATGGAGAAGTCAGAGACTGAGCTCAAGGATACTTATGCTCGTTGG384IleMetGluLysSerGluThrGluLeuLysAspThrTyrAlaArgTrp115120125CTTCCTCTTGGACTGGGTCTCAACCACCTGGGGAAGGGTGAGGCCATC432LeuProLeuGlyLeuGlyLeuAsnHisLeuGlyLysGlyGluAlaIle130135140GAGGCAATCCTGGCTGCACTGGAGGTTGTGTCAGAGCCATTCCGCAGT480GluAlaIleLeuAlaAlaLeuGluValValSerGluProPheArgSer145150155160TTTGCCAACACACTGGTGGATGTGTGTGCATATGCAGGCTCTGGGAAT528PheAlaAsnThrLeuValAspValCysAlaTyrAlaGlySerGlyAsn165170175GTGCTGAAGGTGCAGCAGCTGCTCCACATTTGTAGCGAACACTTTGAC576ValLeuLysValGlnGlnLeuLeuHisIleCysSerGluHisPheAsp180185190TCCAAAGAGAAGGAGGAAGACAAAGACAAGAAGGAAAAGAAAGACAAG624SerLysGluLysGluGluAspLysAspLysLysGluLysLysAspLys195200205GACAAGAAGGAAGCCCCTGCTGACATGGGAGCACATCAGGGAGTGGCT672AspLysLysGluAlaProAlaAspMetGlyAlaHisGlnGlyValAla210215220GTTCTGGGGATTGCCCTTATTGCTATGGGGGAGGAGATTGGTGCAGAG720ValLeuGlyIleAlaLeuIleAlaMetGlyGluGluIleGlyAlaGlu225230235240ATGGCATTACGAACCTTTGGCCACTTGCTGAGATATGGGGAGCCTACA768MetAlaLeuArgThrPheGlyHisLeuLeuArgTyrGlyGluProThr245250255CTCCGGAGGGCTGTACCTTTAGCACTGGCCCTCATCTCTGTTTCAAAT816LeuArgArgAlaValProLeuAlaLeuAlaLeuIleSerValSerAsn260265270CCACGACTCAACATCCTGGATACCCTAAGCAAATTCTCTCATGATGCT864ProArgLeuAsnIleLeuAspThrLeuSerLysPheSerHisAspAla275280285GATCCAGAAGTTTCCTATAACTCCATTTTTGCCATGGGCATGGTGGGC912AspProGluValSerTyrAsnSerIlePheAlaMetGlyMetValGly290295300AGTGGTACCAATAATGCCCGTCTGGCTGCAATGCTGCGCCAGTTAGCT960SerGlyThrAsnAsnAlaArgLeuAlaAlaMetLeuArgGlnLeuAla305310315320CAATATCATGCCAAGGACCCAAACAACCTCTTCATGGTGCGCTTGGCA1008GlnTyrHisAlaLysAspProAsnAsnLeuPheMetValArgLeuAla325330335CAGGGCCTGACACATTTAGGGAAGGGCACCCTTACCCTCTGCCCCTAC1056GlnGlyLeuThrHisLeuGlyLysGlyThrLeuThrLeuCysProTyr340345350CACAGCGACCGGCAGCTTATGAGCCAGGTGGCCGTGGCTGGACTGCTC1104HisSerAspArgGlnLeuMetSerGlnValAlaValAlaGlyLeuLeu355360365ACTGTGCTTGTCTCTTTCCTGGATGTTCGAAACATTATTCTAGGCAAA1152ThrValLeuValSerPheLeuAspValArgAsnIleIleLeuGlyLys370375380TCACACTATGTATTGTATGGGCTGGTGGCTGCCATGCAGCCCCGAATG1200SerHisTyrValLeuTyrGlyLeuValAlaAlaMetGlnProArgMet385390395400CTGGTTACGTTTGATGAGGAGCTGCGGCCATTGCCAGTGTCTGTCCGT1248LeuValThrPheAspGluGluLeuArgProLeuProValSerValArg405410415GTGGGCCAGGCAGTGGATGTGGTGGGCCAGGCTGGCAAGCCGAAGACT1296ValGlyGlnAlaValAspValValGlyGlnAlaGlyLysProLysThr420425430ATCACAGGGTTCCAGACGCATACAACCCCAGTGTTGTTGGCCCACGGG1344IleThrGlyPheGlnThrHisThrThrProValLeuLeuAlaHisGly435440445GAACGGGCAGAATTGGCCACTGAGGAGTTTCTTCCTGTTACCCCCATT1392GluArgAlaGluLeuAlaThrGluGluPheLeuProValThrProIle450455460CTGGAAGGTTTTGTTATCCTTCGGAAGAACCCCAATTATGATCTC1437LeuGluGlyPheValIleLeuArgLysAsnProAsnTyrAspLeu465470475TAAGTGACCACCAGGGGCTCTGAACTGTAGCTGATGTTATCAGCAGGCCATGCATCCTGC1497TGCCAAGGGTGGACACGGCTGCAGACTTCTGGGGGAATTGTCGCCTCCTGCTCTTTTGTT1557ACTGAGTGAGATAAGGTTGTTCAATAAAGACTTTTATCCCCAAAAAAAAAAAAAAAAAAA1617AAAAAAAAAAAAAA1631(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 479 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:AspLysTyrLeuTyrSerSerGluAspTyrIleLysSerGlyAlaLeu151015LeuAlaCysGlyIleValAsnSerGlyValArgAsnGluCysAspPro202530AlaLeuAlaLeuLeuSerAspTyrValLeuHisAsnSerAsnThrMet354045ArgLeuGlySerIlePheGlyLeuGlyLeuAlaTyrAlaGlySerAsn505560ArgGluAspValLeuThrLeuLeuLeuProValMetGlyAspSerLys65707580SerSerMetGluValAlaGlyValThrAlaLeuAlaCysGlyMetIle859095AlaValGlySerCysAsnGlyAspValThrSerThrIleLeuGlnThr100105110IleMetGluLysSerGluThrGluLeuLysAspThrTyrAlaArgTrp115120125LeuProLeuGlyLeuGlyLeuAsnHisLeuGlyLysGlyGluAlaIle130135140GluAlaIleLeuAlaAlaLeuGluValValSerGluProPheArgSer145150155160PheAlaAsnThrLeuValAspValCysAlaTyrAlaGlySerGlyAsn165170175ValLeuLysValGlnGlnLeuLeuHisIleCysSerGluHisPheAsp180185190SerLysGluLysGluGluAspLysAspLysLysGluLysLysAspLys195200205AspLysLysGluAlaProAlaAspMetGlyAlaHisGlnGlyValAla210215220ValLeuGlyIleAlaLeuIleAlaMetGlyGluGluIleGlyAlaGlu225230235240MetAlaLeuArgThrPheGlyHisLeuLeuArgTyrGlyGluProThr245250255LeuArgArgAlaValProLeuAlaLeuAlaLeuIleSerValSerAsn260265270ProArgLeuAsnIleLeuAspThrLeuSerLysPheSerHisAspAla275280285AspProGluValSerTyrAsnSerIlePheAlaMetGlyMetValGly290295300SerGlyThrAsnAsnAlaArgLeuAlaAlaMetLeuArgGlnLeuAla305310315320GlnTyrHisAlaLysAspProAsnAsnLeuPheMetValArgLeuAla325330335GlnGlyLeuThrHisLeuGlyLysGlyThrLeuThrLeuCysProTyr340345350HisSerAspArgGlnLeuMetSerGlnValAlaValAlaGlyLeuLeu355360365ThrValLeuValSerPheLeuAspValArgAsnIleIleLeuGlyLys370375380SerHisTyrValLeuTyrGlyLeuValAlaAlaMetGlnProArgMet385390395400LeuValThrPheAspGluGluLeuArgProLeuProValSerValArg405410415ValGlyGlnAlaValAspValValGlyGlnAlaGlyLysProLysThr420425430IleThrGlyPheGlnThrHisThrThrProValLeuLeuAlaHisGly435440445GluArgAlaGluLeuAlaThrGluGluPheLeuProValThrProIle450455460LeuGluGlyPheValIleLeuArgLysAsnProAsnTyrAspLeu465470475(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:TACGGCACTCTTATACTAAGGATTTTCACCCGT33(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:ATTGACCAGAGTTGTCTAGGCACTCTTATAAAT33(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:TCATTTTCCCTCATACTACGGATTGACCACAGT33(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 33 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:GTCCCATTTGGCATTCTATTTCTCCTTTTCAAA33(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 47 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:LysLeuLeuMetIleIleHisAspArgArgGluPheAlaLysPheGlu151015LysGluLysMetAsnAlaLysTrpAspThrGlyGluAsnProIleTyr202530LysSerAlaValThrThrValValAsnProLysTyrGluGlyLys354045(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:LysLeuMetIleIleHisAspArgArgGluPheAlaLysPheGluLys151015GluLysMetAsnAlaLysTrpAspThrGlyGluAsnPro2025(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:LysLeuLeuMetIleIleHisAspArgArgGluPheAlaLysPheGlu151015LysGluLysMetAsnAlaLysTrpAspThrGlyGluAsnProIleTyr202530LysSerAla35(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 42 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:LysLeuLeuMetIleIleHisAspArgArgGluPheAlaLysPheGlu151015LysGluLysMetAsnAlaLysTrpAspThrGlyGluAsnProIleTyr202530LysSerAlaValThrThrValValAsnPro3540(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:LysLeuLeuMetIleIleHisAspArgArgGluPheAlaLysPheGlu151015LysGluLys__________________________________________________________________________

Claims

1. A method for identifying a compound that modulates binding between TRAP2/26S proteasome subunit and .beta..sub.1 integrin comprising the steps of:

a) contacting TRAP2/26S proteasome subunit or a fragment thereof, with integrin or a fragment thereof;

b) measuring binding between TRAP2/26S proteasome subunit or a fragment thereof, and .beta..sub.1 integrin or a fragment;

c) measuring binding between TRAP2/26S proteasome subunit or a fragment thereof, and .beta..sub.1 integrin or a fragment in the presence of a test compound; and

d) comparing the measurement in step (b) and the measurement in step (c) wherein a decrease in binding in step (c) indicates the test compound in an inhibitor of binding, and an increase in binding in step (c) indicates the test compound is an activator of binding.